You may also like

EQRx Taps Zeitgeist, Raises $200m For Innovative Drugs at Aggressive Low Prices
Third Rock and Friends Bet $110M On Thrive, a Hopkins-Inspired Cancer Screening Startup
Betting on Biotech IPOs? What If You Buy the Third Rock and ARCH Portfolios?
Third Rock’s Tango Gets $55M for CRISPR-Enabled Synthetic Lethal Cancer Combos